Yacoub, A., Mascarenhas, J., Kosiorek, H. E., Prchal, J. T., Berenzon, D., Baer, M. R., … Hoffman, R. (2017). Single-Arm Salvage Therapy with Pegylated Interferon Alfa-2a for Patients with High-Risk Polycythemia Vera or High-Risk Essential Thrombocythemia Who Are Either Hydroxyurea-Resistant or Intolerant: Final Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Phase II Trial. In BLOOD (Vol. 130). Atlanta, GA: AMER SOC HEMATOLOGY.

Yacoub, Abdulraheem, John Mascarenhas, Heidi Elizabeth Kosiorek, Josef T. Prchal, Dmitriy Berenzon, Maria R. Baer, Ellen K. Ritchie, et al. “Single-Arm Salvage Therapy with Pegylated Interferon Alfa-2a for Patients with High-Risk Polycythemia Vera or High-Risk Essential Thrombocythemia Who Are Either Hydroxyurea-Resistant or Intolerant: Final Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Phase II Trial.” In BLOOD, Vol. 130. AMER SOC HEMATOLOGY, 2017.

Yacoub A, Mascarenhas J, Kosiorek HE, Prchal JT, Berenzon D, Baer MR, et al. Single-Arm Salvage Therapy with Pegylated Interferon Alfa-2a for Patients with High-Risk Polycythemia Vera or High-Risk Essential Thrombocythemia Who Are Either Hydroxyurea-Resistant or Intolerant: Final Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Phase II Trial. In: BLOOD. AMER SOC HEMATOLOGY; 2017.

Yacoub, Abdulraheem, et al. “Single-Arm Salvage Therapy with Pegylated Interferon Alfa-2a for Patients with High-Risk Polycythemia Vera or High-Risk Essential Thrombocythemia Who Are Either Hydroxyurea-Resistant or Intolerant: Final Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Phase II Trial.” BLOOD, vol. 130, AMER SOC HEMATOLOGY, 2017.

Yacoub A, Mascarenhas J, Kosiorek HE, Prchal JT, Berenzon D, Baer MR, Ritchie EK, Silver RT, Kessler CM, Winton EF, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz DS, Rondelli D, Arcasoy MO, Catchatourian R, Vadakara J, Rosti V, Hexner E, Kremyanskaya M, Orellana A, Sandy L, Tripodi J, Najfeld V, Salama ME, Weinberg RS, Rampal RK, Mesa RA, Goldberg JD, Dueck AC, Hoffman R. Single-Arm Salvage Therapy with Pegylated Interferon Alfa-2a for Patients with High-Risk Polycythemia Vera or High-Risk Essential Thrombocythemia Who Are Either Hydroxyurea-Resistant or Intolerant: Final Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Phase II Trial. BLOOD. AMER SOC HEMATOLOGY; 2017.